Obicetrapib/ezetimibe is an experimental fixed-dose combination medication intended for the treatment of primary hypercholesterolemia (high cholesterol) or mixed dyslipidemia. It contains obicetrapib, as the salt obicetrapib hemicalcium, a lipid-modifying agent; and ezetimibe, a lipid-modifying agent. Obicetrapib blocks a blood protein called CETP thereby lowering the level of LDL cholesterol. Ezetimibe blocks a protein in the gut wall (NPC1L1) that absorbs cholesterol from food and bile, leading to decreased blood levels of LDL cholesterol. It is taken by mouth.
Society and culture Legal status In July 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Evlarco, intended for the treatment of primary hypercholesterolemia (high cholesterol) or mixed dyslipidemia. The applicant for this medicinal product is A. Menarini International Licensing. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
References